Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group IND.172 -- Primary Publication
Phase II Study of Bortezomib and Gemcitabine in Patients with Relapsed Mantle Cell Lymphoma

Kouroukis CT, Fernandez LAV, Crump M, Chua NS, Buckstein R, Turner R, Assouline S, Klasa RJ, Walsh W, Powers J, Eisenhauer E. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 52: 394-9, 2011.

Meta-Analysis, including Canadian Cancer Trials Group BR.10
A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer

Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P, for the LACE-Bio Group. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: Analysis of four randomized trials (ONLINE). Ann Oncol 2011.